Alnylam Pharmaceuticals reported an outstanding second-quarter performance driven by its rare disease drug Amvuttra, with sales more than doubling year over year to $492 million. The drug’s uptake in transthyretin amyloidosis cardiomyopathy (ATTR-CM) has been broad and balanced, including patients progressing on earlier therapies and across different clinical settings. Majority of targeted health systems have placed Amvuttra on formulary, providing comprehensive access. These robust commercial results have lifted Alnylam’s market capitalization beyond $50 billion and led to increased revenue outlooks, underpinning the company’s leadership in RNA interference therapeutics.